The in vivo preclinical studies on anti-neoplastic function and toxicological evaluation of PB substantiate that it could be a potential candidate for monotherapy as well as combination therapy with PARP inhibitors or other standard chemotherapeutics for BRCA1-defective cancer treatment. Here, PARP1 is linked to cancer.